Results 151 to 160 of about 8,375,389 (400)

Cisplatin and Beyond: Molecular Mechanisms of Action and Drug Resistance Development in Cancer Chemotherapy

Radiology and Oncology, 2019
Background Platinum-based anticancer drugs are widely used in the chemotherapy of human neoplasms. The major obstacle for the clinical use of this class of drugs is the development of resistance and toxicity.
T. Makovec
semanticscholar   +1 more source

Determination of ADP/ATP translocase isoform ratios in malignancy and cellular senescence

Molecular Oncology, EarlyView.
The individual functions of three isoforms exchanging ADP and ATP (ADP/ATP translocases; ANTs) on the mitochondrial membrane remain unclear. We developed a method for quantitatively differentiating highly similar human ANT1, ANT2, and ANT3 using parallel reaction monitoring. This method allowed us to assess changes in translocase levels during cellular
Zuzana Liblova, Dominika Maurencova, Barbora Salovska, Marek Kratky, Tomas Mracek, Zuzana Korandova, Alena Pecinova, Pavla Vasicova, David Rysanek, Ladislav Andera, Ivo Fabrik, Rudolf Kupcik, Pavel Kashmel, Pinky Sultana, Vojtech Tambor, Jiri Bartek, Josef Novak, Marie Vajrychova, Zdenek Hodny   +18 more
wiley   +1 more source

Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. [PDF]

, 2014
Adequate clinical and parasitologic cure by artemisinin combination therapies relies on the artemisinin component and the partner drug. Polymorphisms in the Plasmodium falciparum chloroquine resistance transporter (pfcrt) and P.
Adam, Ishag, Ademowo, George, Arze, Cesar, Asaq Molecular Marker Study Group, Baliraine, Frederick N, Berens-Riha, Nicole, Björkman, Anders, Borrmann, Steffen, Checchi, Francesco, Dahal, Prabin, Davis, Timothy ME, Desai, Meghna, Dhorda, Mehul, Djimdé, Abdoulaye A, Dorsey, Grant, El-Sayed, Badria B, Eshetu, Teferi, Eyase, Frederick, Falade, Catherine, Faucher, Jean-François, Fröberg, Gabrielle, Gadalla, Nahla B, Grivoyannis, Anastasia, Guérin, Philippe, Hamour, Sally, Houzé, Sandrine, Johnson, Jacob, Kamugisha, Erasmus, Kariuki, Simon, Kiechel, Jean-René, Kironde, Fred, Kofoed, Poul-Erik, LeBras, Jacques, Malmberg, Maja, Moriera, Clarissa, Mwai, Leah, Mårtensson, Andreas, Ménard, Didier, Ngasala, Billy, Nosten, Francois, Nsanzabana, Christian, Nsobya, Samuel L, Nzila, Alexis, Oguike, Mary, Ogutu, Bernhards, Otienoburu, Sabina Dahlström, Ouédraogo, Jean-Bosco, Piola, Patrice, Plowe, Christopher V, Price, Ric N, Rombo, Lars, Rosenthal, Philip J, Schramm, Birgit, Sibley, Carol Hopkins, Somé, A Fabrice, Stepniewska, Kasia, Sutherland, Colin J, Thwing, Julie, Ursing, Johan, Venkatesan, Meera, Wong, Rina PM, Zeynudin, Ahmed, Zongo, Issaka   +62 more
core   +3 more sources

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

Chemical approaches to targeting drug resistance cancer stem cells [PDF]

, 2016
STEMCHEM is a COST action aiming to target causes of drug resistance in cancer stem cells. Cancer stem cells are cells which are believed to be responsible for the larger part of the regenerative capacity of cancers.
Blaire Theuma, Krystle, Cassar, Analisse, Micallef, Neville, Passarella, Daniele, Schembri-Wismayer, Pierre, Stipourou, Iona, Suleiman, Sherif   +6 more
core   +1 more source

Drug Resistance in Cancer: An Overview

Cancers, 2014
Cancers have the ability to develop resistance to traditional therapies, and the increasing prevalence of these drug resistant cancers necessitates further research and treatment development.
Genevieve Housman, Shannon Byler, S. Heerboth, K. Lapinska, Mckenna Longacre, N. Snyder, S. Sarkar   +6 more
semanticscholar   +1 more source

ETHICS AND DRUG RESISTANCE

Bioethics, 2007
ABSTRACTThis paper reviews the dynamics behind, and ethical issues associated with, the phenomenon of drug resistance. Drug resistance is an important ethical issue partly because of the severe consequences likely to result from the increase in drug resistant pathogens if more is not done to control them.
openaire   +4 more sources

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Sudapyridine (WX-081) antibacterial activity against Mycobacterium avium, Mycobacterium abscessus, and Mycobacterium chelonae in vitro and in vivo

mSphere
Sudapyridine (WX-081) is a structural analog of bedaquiline (BDQ), which shows anti-tuberculosis and non-tuberculous mycobacteria (NTM) activities but, unlike BDQ, did not prolong QT interval in animal model studies.
Luyao Zheng, Hong Wang, Xueting Qi, Weiyan Zhang, Bin Wang, Lei Fu, Xi Chen, Xiaoyou Chen, Yu Lu   +8 more
doaj   +1 more source

Predicting drug resistance

eLife
A new approach helps examine the proportion of cancerous and healthy stem cells in patients with chronic myeloid leukemia and how this influences treatment outcomes.
Nicole S Arellano, Shannon E Elf
openaire   +3 more sources